Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Cannabis, Cannabinoide und das Endocannabinoidsystem

  • Chapter
Cannabis: Potenzial und Risiko

  • 6792 Accesses

Zusammenfassung

Die Nutzung der Hanfpflanze (Cannabis L.) und ihrer Produkte durch den Menschen zu religiösen und medizinischen Zwecken, aber auch wegen ihrer euphorischen und entspannenden Wirkung, reicht tausende von Jahren zurück. Der Hanf gehört ebenso wie die Gattung Humulus (Hopfen) der Familie der Cannabaceae (Hanfgewächse) an. Die Anzahl der Arten in der Gattung Cannabis wurde lange diskutiert und bleibt weiterhin umstritten. Gegenstand der Debatte war die Frage, ob Cannabis sativa, Cannabis indica und Cannabis ruderalis jeweils eigene Arten darstellen. Aktuell wird meist eine einzige vielfältige Art (Cannabis sativa L.) mit verschiedenen Variationen angenommen, andere Forscher plädieren dagegen für eine Unterteilung in zwei getrennte Arten (Cannabis sativa und Cannabis indica).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alger BE (2012) Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. J Physiol 590 (10): 2203–2212

    Google Scholar 

  2. Ameri A (1999) The effects of cannabinoids on the brain. Progress in neurobiology 58 (4): 315–348

    Google Scholar 

  3. Argue KJ, VanRyzin JW, Falvo DJ, Whitaker AR, Yu SJ, McCarthy MM (2017) Activation of Both CB1 and CB2 Endocannabinoid Receptors is critical for masculinization of the developing medial Amygdala and Juvenile Social Play Behavior. eNeuro 4 (1): 0344–0316.2017. doi: 10.1523/ENEURO.0344-16.2017.

  4. Atwood BK, Mackie K (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160 (3): 467–479

    Google Scholar 

  5. Baik J-H (2013) Dopamine signaling in reward-related behaviors. Frontiers in neural circuits 7

    Google Scholar 

  6. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995) The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17 (1): 25–30

    Google Scholar 

  7. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316 (5828): 1212–1216

    Google Scholar 

  8. Berrendero F, Sepe N, Ramos JA, Di Marzo V, Fernández-Ruiz JJ (1999) Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 33 (3): 181–191

    Google Scholar 

  9. Blankman JL, Cravatt BF (2013) Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65 (2): 849–871

    Google Scholar 

  10. Brents LK (2016) Marijuana, the Endocannabinoid System and the Female Reproductive System. Yale J Biol Med 89 (2): 175–191

    Google Scholar 

  11. Brown A (2007) Novel cannabinoid receptors. Br J Pharmacol 152 (5): 567–575

    Google Scholar 

  12. Buczynski MW, Parsons LH (2010) Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. Br J Pharmacol 160 (3): 423–442

    Google Scholar 

  13. Busquets-Garcia A, Bains J, Marsicano G (2017) CB1 Receptors signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. doi: 10.1038/npp.2017.206

  14. Cahill L (2006) Why sex matters for neuroscience. Nature Rev Neurosci 7 (6): 477

    Google Scholar 

  15. Cascini F, Aiello C, Di Tanna G (2012) Inreasing delta-9-tetrahydrocannabinol content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 5 (1): 32–40

    Google Scholar 

  16. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12–41. doi: 10.1016/j.drugalcdep.2014.08.005

  17. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76 (1): 70–81. doi: 10.1016/j.neuron.2012.09.020

  18. Choi K, Le T, McGuire J, Xing G, Zhang L, Li H, Parker CC, Johnson LR, Ursano RJ (2012) Expression pattern of the cannabinoid receptor genes in the frontal cortex of mood disorder patients and mice selectively bred for high and low fear. J Psychiatr Res 46 (7): 882–889. doi: 10.1016/j.jpsychires.2012.03.021

  19. Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009

  20. de Fonseca FR, Ramos JA, Bonnin A, Fernández-Ruiz JJ (1993) Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4 (2): 135–138

    Google Scholar 

  21. Devane WA, Dysarz Fr, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (5): 605–613

    Google Scholar 

  22. Diaz-Alonso J, Aguado T, Wu C-S, Palazuelos J, Hofmann C, Garcez P, Guillemot F, Lu H-C, Lutz B, Guzman M, Galve-Roperh I (2012) The CB (1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. J Neurosci 32 (47): 16651–16665. doi: 10.1523/JNEUROSCI.0681-12.2012

  23. Diaz S, Farhang B, Hoien J, Stahlman M, Adatia N, Cox JM, Wagner EJ (2009) Sex differences in the cannabinoid modulation of appetite, body temperature and neurotransmission at POMC synapses. Neuroendocrinology 89 (4): 424–440

    Google Scholar 

  24. Du Plessis SS, Agarwal A, Halabi J, Tvrda E (2015) Contemporary evidence on the physiological role of reactive oxygen species in human sperm function. J Assist Reprod Genet 32 (4): 509–520

    Google Scholar 

  25. Dujourdy L, Besacier F (2017) A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int 272: 72–80. doi: 10.1016/j.forsciint.2017.01.007

  26. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142 (3): 295–301

    Google Scholar 

  27. El Khoury M-A, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET (2012) Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuro-Psychopharmacol Biol Psychiat 38 (1): 36–50

    Google Scholar 

  28. Elphick MR (2012) The evolution and comparative neurobiology of endocannabinoid signalling. Philos Trans R Soc London Ser B Biol Sci 367 (1607): 3201–3215. doi: 10.1098/rstb.2011.0394

  29. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004

  30. ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 103: 1–36. doi: 10.1007/978-3-319-45541-9_1

  31. Esteban S, García-Sevilla JA (2012) Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiat 38 (1): 78–87

    Google Scholar 

  32. Fattore L, Fratta W (2010) How important are sex differences in cannabinoid action? Br J Pharmacol 160 (3): 544–548

    Google Scholar 

  33. Fernández-Ruiz J, Berrendero F, Hernandez M, Romero J, Ramos J (1999) Role of endocannabinoids in brain development. Life Sci 65 (6): 725–736

    Google Scholar 

  34. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23 (1): 14–20

    Google Scholar 

  35. Friedman D, Sirven J (2017) Historical perspective on the medial use of cannabis for epilepsy: Ancient times to the 1980s. Epilepsy Behav 70 (Pt B): 298–301. doi: 10.1016/j.yebeh.2016.11.033

  36. Fügedi G, Molnár M, Rigó J, Schönléber J, Kovalszky I, Molvarec A (2014) Increased placental expression of cannabinoid receptor 1 in preeclampsia: an observational study. BMC pregnancy and childbirth 14 (1): 395

    Google Scholar 

  37. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. The FEBS J 232 (1): 54–61

    Google Scholar 

  38. Garcia AB, Soria-Gomez E, Bellocchio L, Marsicano G (2016a) Cannabinoid receptor type-1: breaking the dogmas. F1000Research 5

    Google Scholar 

  39. Garcia C, Palomo-Garo C, Gomez-Galvez Y, Fernandez-Ruiz J (2016b) Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol 173 (13): 2069–2079. doi: 10.1111/bph.13215

  40. Garcia MC, Cinquina V, Palomo-Garo C, Rabano A, Fernandez-Ruiz J (2015) Identification of CB (2) receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett 587: 1–4. doi: 10.1016/j.neulet.2014.12.003

  41. Gertsch J, Pertwee RG, Di Marzo V (2010) Phytocannabinoids beyond the Cannabis plant – do they exist? Br J Pharmacol 160 (3): 523–529. doi: 10.1111/j.1476-5381.2010.00745.x

  42. Giedd JN, Raznahan A, Mills KL, Lenroot RK (2012) magnetic resonance imaging of male/female differences in human adolescent brain anatomy. Biology of Sex Differences 3 (1): 19

    Google Scholar 

  43. Giuffrida A, Parsons L, Kerr T, deFonseca FR, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature neuroscience 2 (4)

    Google Scholar 

  44. Hermann D, Schneider M (2012) Potential protective effects of cannabidiol onneuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharmaceut Design 18 (32): 4897–4905

    Google Scholar 

  45. Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss U (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Aerzteblatt Int 112 (16): 271–278. doi: 10.3238/arztebl.2015.0271

  46. Hu SS-J, Mackie K (2015) Distribution of the endocannabinoid system in the central nervous system. In: Endocannabinoids. Springer, pp 59–93

    Google Scholar 

  47. James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: 10.1016/j.pscychresns.2013.07.012

  48. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89 (1): 309–380. doi: 10.1152/physrev.00019.2008

  49. Katona I, Freund T (2012) Multiple funktions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35: 529–558. doi: 10.1146/annurev-neuro-062111-150420

  50. Kendall DA, Yudowski GA (2016) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Frontiers in cellular neuroscience 10

    Google Scholar 

  51. Klugmann M, Klippenstein V, Leweke FM, Spanagel R, Schneider M (2011) Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels. International J Neuropsychopharmacology 14 (4): 505–517

    Google Scholar 

  52. Krebs-Kraft DL, Hill MN, Hillard CJ, McCarthy MM (2010) Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proceedings of the National Academy of Sciences 107 (47): 20535–20540

    Google Scholar 

  53. Laursen L (2015) Botany: The cultivation of weed. Nature neuroscience 525 (7570): S4–5. doi: 10.1038/525S4a

  54. Ligresti A, Villano R, Allara M, Ujvary I, Di Marzo V (2012) Kavalactones and the endocannabinoid system: the plant-derived yangonin is a novel CB (1) receptor ligand. Pharmacol Res 66 (2): 163–169. doi: 10.1016/j.phrs.2012.04.003

  55. Long LE, Lind J, Webster M, Weickert CS (2012) Developmental trajectory of the endocannabinoid system in human dorsolateral prefrontal cortex. BMC Neuroscience 13: 87–87. doi: 10.1186/1471-2202-13-87

  56. López HH (2010) Cannabinoid-hormone interactions in the regulation of motivational processes. Hormones and behavior 58 (1): 100–110

    Google Scholar 

  57. Lu H-C, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiat 79 (7): 516–525

    Google Scholar 

  58. Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nature Rev Neurosci 16 (12): 705–718. doi: 10.1038/nrn4036

  59. Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36 (5): 277–296. doi: 10.1016/j.tips.2015.02.008

  60. Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014) Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. 2014 15 (12): 786–801. doi: 10.1038/nrn3846

  61. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Cannabinoids: 299–325

    Google Scholar 

  62. Malfitano AM, Basu S, Maresz K, Bifulco M, Dittel BN What we know and do not know about the cannabinoid receptor 2 (CB2). In: Seminars in immunology, 2014. vol 5. Elsevier, pp 369–379

    Google Scholar 

  63. Mato S, Del Olmo E, Pazos A (2003) Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. European J Neuroscience 17 (9): 1747–1754

    Google Scholar 

  64. Mato S, Pazos A (2004) Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46 (5): 716–726

    Google Scholar 

  65. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bronner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (6284): 561

    Google Scholar 

  66. McEwen BS, Milner TA (2017) Understanding the broad influence of sex hormones and sex differences in the brain. J neuroscience research 95 (1–2): 24–39

    Google Scholar 

  67. McLaughlin CR, Martin BR, Compton DR, Abood ME (1994) Cannabinoid receptors in developing rats: detection of mRNA and receptor binding. Drug Alcohol Depend 36 (1): 27–31

    Google Scholar 

  68. McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol und Delta (9)-tetrahydrocannabivarin negative modulators or the endocannabinoid system? A systematic review. Br J Pharmacol 172 (3): 737.753. doi: 10.1111/bph.12944

  69. Mechoulam R, Hanus LO, Pertwee R, Howlett AC (2014) Early phytocannabinoid chemistry to endocannabinoids and beyond. Nature Rev Neurosci 15 (11): 757–764. doi: 10.1038/nrn3811

  70. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109 (40): E2657–2664. doi: 10.1073/pnas.1206820109

  71. Melis M, Pistis M (2012) Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Phil Trans R Soc B 367 (1607): 3276–3285

    Google Scholar 

  72. Meyer HC, Lee FS, Gee DG (2017) The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology. doi: 10.1038/npp.2017.143

  73. Monshouwer K, Smit F, de Graaf R, van Os J, Vollebergh W (2005) First cannabis use: does onset shift to younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 100 (7): 963–970. doi: 10.1111/j.1360-0443.2005.01088.x

  74. Morales P, Hurst DP, Reggio PH (2017) Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod 103: 103–131. doi: 10.1007/978-3-319-45541-9_4

  75. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, Monory K, Marsicano G, Di Marzo V, Hurd YL, Guillemot F, Mackie K, Lutz B, Guzman M, Lu H-C, Galve-Roperh I, Harkany T (2008) Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci USA 105 (25): 8760–8765. doi: 10.1073/pnas.0803545105

  76. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (6441): 61–65

    Google Scholar 

  77. Orsolini L, Papanti D, Corkery J, De Luca MA, Cadoni C, Di Chiara G, Schifano F (2017) Is there a teratogenicity risk associated with cannabis and synthetic cannabimimetics” („Spice”) intake? CNS Neurol Disord Drug Targets. doi: 10.2174/1871527316666170413101257

  78. Pavlova MA (2016) Sex and gender affect the social brain: beyond simplicity. J neuroscience research

    Google Scholar 

  79. Pertwee R (2012) Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 367 (1607): 3353–3363. doi: 10.1098/rstb.2011.0381

  80. Pertwee RG (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 73 (1): 96–105. doi: 10.1017/s0029665113003649

  81. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nature Rev Neurosci 4 (11): 873

    Google Scholar 

  82. Richardson KA, Hester AK, McLemore GL (2016) Prenatal cannabis exposure-The „first hit” to the endocannabinoid system. Neurotoxicol Teratol 58: 5–14

    Google Scholar 

  83. Russo E (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & biodiversity 4 (8): 1614–1648

    Google Scholar 

  84. Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263. doi: 10.1111/j.1369-1600.2008.00110.x

  85. Schneider M (2009) Cannabis use in pregnancy and early life and its consequences: animal models. Eur Arch Psychiat Clin Neurosci 259 (7): 383–393. doi: 10.1007/s00406-009-0026-0

  86. Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell tissue Res 354 (1): 99–106. doi: 10.1007/s00441-013-1581-2

  87. Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, Steindel F, Monory K, Schafer C, Miederer I, Leweke FM, Schreckenberger M, Lutz B, Reggio PH, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988. doi: 10.1523/jneurosci.1937-15.2015

  88. Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Muller CP (2017) Lipids in psychiatric disorders and preventive medicine. Neurosci Biobehav Rev 76 (Pt B): 336–362. doi: 10.1016/j.neurobiorev.2016.06.002

  89. Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ (2013) Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Progress in neurobiology 106: 1–16

    Google Scholar 

  90. Sierra S, Luquin N, Rico AJ, Gomez-Bautista V, Roda E, Dopeso-Reyes IG, Vazquez A, Martinez-Pinilla E, Labandeira-Garcia JL, Franco R, Lanciego JL (2015) Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism. Brain structure & function 220 (5): 2721–2738. doi: 10.1007/s00429-014-0823-8

  91. Smith TH, Sim-Selley LJ, Selley DE (2010) Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160 (3): 454–466

    Google Scholar 

  92. Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1 (1): 81–98

    Google Scholar 

  93. Sossin WS, DesGroseillers L (2006) Intracellular trafficking of RNA in neurons. Traffic (Copenhagen, Denmark) 7 (12): 1581–1589. doi: 10.1111/j.1600-0854.2006.00500.x

  94. Stempel AV, Stumpf A, Zhang H-Y, Ozdogan T, Pannasch U, Theis A-K, Otte D-M, Wojtalla A, Racz I, Ponomarenko A, Xi Z-X, Zimmer A, Schmitz D (2016) Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus. doi: 10.1016/j.neuron.2016.03.034

  95. Svizenska I, Dubovy P, Sulcova A (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures – a short review. Pharmacol Biochem Behav 90 (4): 501–511. doi: 10.1016/j.pbb.2008.05.010

  96. Swift W, Wong A, Arnold J, MdGregor I (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS one 8 (7): e70052. doi: 10.1371/journal.pone.0070052. Print 2013

  97. Tortoriello G, Morris C, Alpar A, Fuzik J, Shirran SL, Calvigiono D, Keimpema E, Botting CH, Reinecke K, Herdegen T, Courtney M, Hurd YL, Harkany T (2014) Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33 (7): 668–685. doi: 10.1002/embj.201386035

  98. Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martiin-Garcia E, Kasanetz F, Baillie GL, Panin F, Cathala A, Roullot-Lacarriere V, Fabre S, Hurst DP, Lynch DL, Shore DM, Deroche-Gamonet V, Spampinato U, Revest J-M, Maldonado R, Reggio PH, Ross RA, Marsicano G, Piazza PV (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343 (6166): 94–98. doi: 10.1126/science.1243975

  99. van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29 (3): 254–263. doi: 10.1177/0269881114565142

  100. van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480 (1): 133–150

    Google Scholar 

  101. Vinals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de La Torre R, Gasperini P, Navarro G, Howell LA, Pardo L, Lluis C, Canela EI, McCormick PJ, Maldonado R, Robledo P (2015) Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLOS Biol 13 (7): e1002194. doi: 10.1371/journal.pbio.1002194.

  102. Wenger T, Croix D, Tramu G (1988) The effect of chronic prepubertal administration of marihuana (delta-9-tetrahydrocannabinol) on the onset of puberty and the postpubertal reproductive functions in female rats. Biology of reproduction 39 (3): 540–545

    Google Scholar 

  103. Wenger T, Gerendai I, Fezza F, González S, Bisogno T, Fernandez-Ruiz J, Di Marzo V (2002) The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci 70 (12): 1407–1414

    Google Scholar 

  104. Westlake T, Howlett A, Bonner T, Matsuda L, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63 (3): 637–652

    Google Scholar 

  105. Wu C-S, Zhu J, Wager-Miller J, Wang S, O’Leary D, Monory K, Lutz B, Mackie K, Lu H-C (2010) Requirement of cannabinoid CB (1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci 32 (5): 693–706. doi: 10.1111/j.1460-9568.2010.07337.x.

  106. Zamengo L, Frison G, Bettin C, Sciarrone R (2015) Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal 7 (3): 255–258. doi: 10.1002/dta.1690

  107. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, Gardner EL, Wu J, Xi ZX (2014) Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci USA 111 (46): E5007–5015. doi: 10.1073/pnas.1413210111

  108. Zurolo E, Iyer AM, Spliet WG, Van Rijen PC, Troost D, Gorter JA, Aronica E (2010) CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies. Neuroscience 170 (1): 28–41. doi: 10.1016/j.neuroscience.2010.07.004

  109. Zygmunt PM, Petersson J, Andersson DA, Chuang H-h, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (6743): 452–457

    Google Scholar 

  110. Baumgärtner T, Kestler J (2014) Suchtmittelgebrauch, Computerspielverhalten, Internetnutzung und Glücksspielerfahrungen von Jugendlichen in Hamburg und5 kommunalen Modellregionen in Deutschland. Deskriptive Ergebnisse der SCHULBUSregional-Studie 2012 HLS/BfS Berichte SB 14-B1: Hamburg: Büro für Suchtprävention der Hamburgischen Landesstelle für Suchtfragen e. V.

    Google Scholar 

  111. BZgA (2015) Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland 2014. Ergebnisse einer aktuellen Repräsentationsbefragung und Trends. Köln: Bundeszentrale für gesundheitliche Aufklärung

    Google Scholar 

  112. Cao D, Srisuma S, Bronstein A, Hoyte C (2016) Characterization of edible marijuana product exposures reported to United States poison centers. J Clinical Toxicology 54: 840–846

    Google Scholar 

  113. Dauber H, Specht S, Künzel J, Braun B (2016) Suchthilfe in Deutschland 2015. Jahresbericht der Deutschen Suchthilfestatistik. IFT München

    Google Scholar 

  114. EMCDDA (2009) European Monitoring Center for Drugs and Drug Addiction. Polydrug use: patterns and responses. Publications Office of the European Union, Luxembourg

    Google Scholar 

  115. EMCDDA (2013) European Monitoring Center for Drugs and Drug Addiction. Characteristics of frequent and high-risk cannabis users. Perspectives on drugs (available at emcddaeuropaeu/topics/pods/frequent-cannabis-users)

    Google Scholar 

  116. EMCDDA (2015) European Monitoring Center for Drugs and Drug Addiction. Treatment of cannabis-related disorders in Europe. Insight Publication 17. Publications Office of the European Union, Luxembourg

    Google Scholar 

  117. EMCDDA (2016) European Monitoring Center for Drugs and Drug Addiction. Europäischer Drogenbericht 2016: Trends und Entwicklungen. Amt für Veröffentlichungen der Europäischen Union, Luxemburg

    Google Scholar 

  118. EMCDDA (2017a) European Monitoring Center for Drugs and Drug Addiction. Europäischer Drogenbericht 2017: Trends und Entwicklungen. Amt für Veröffentlichungen der Europäischen Union, Luxemburg

    Google Scholar 

  119. EMCDDA (2017b) European Monitoring Center for Drugs and Drug Addiction. News release council decision. http://emcdda.europa.eu/news/2017/3/council-decision-control-mdmb-chmica.

  120. ESPAD (2016) ESPAD Report 2015. Results from the European School Survey Project on Alcohol and Other Drugs. Publications Office of the European Union, Luxembourg

    Google Scholar 

  121. Fergusson D, Boden J, Horwood L (2008) The develpmental antecedents of illicit drug use: evidence from a 25-year longitudinal study. Drug Alcohol Depend 96 (1): 165–177

    Google Scholar 

  122. Gomes de Matos E, Atzendorf J, Kraus L, Piontek D (2016) Substanzkonsum in der Allgemeinbevölkerung in Deutschland. Ergebnisse des Epidemiologischen Suchtsurveys 2015. Sucht 62 (5): 271–281

    Google Scholar 

  123. Hall W (2014) What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 110: 19–35

    Google Scholar 

  124. Hall W, Pacula R (2003) Cannabis use and dependence: public health and public policy. Cambridge University Press

    Google Scholar 

  125. Höhne B, Pabst A, Hannemann T, Kraus L (2014) Patterns of concurrent alcohol, tobacco, and cannabis use in Germany: Prevalence and correlates. Drugs: Education, Prevention & Policy 21 (2): 102–109

    Google Scholar 

  126. Kraus L, Piontek D, Atzendorf J, Gomes de Matos E (2016a) Zeitliche Entwicklungen im Substanzkonsum in der deutschen Allgemeinbevölkerung. Ein Rückblick auf zwei Dekaden. Sucht 62: 283–294

    Google Scholar 

  127. Kraus L, Piontek D, Seitz N, Schoeppe M (2016b) Europäische Schülerstudie zu Alkohol und anderen Drogen 2015 (ESPAD): Befragungen der Schülerinnen und Schüler der 9. und 10. Klasse in Bayern. IFT-Berichte Bd. 188. IFT Institut für Therapieforschung, München

    Google Scholar 

  128. Lynskey M, Heath A, Bucholz K, Slutske W, Madden P, Nelson E, NG M (2003) Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA Psychiatry 289 (4): 427–433

    Google Scholar 

  129. Lynskey M, Vink J, Boomsma D (2006) Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet 36 (2): 195

    Google Scholar 

  130. Morral A, McCaffre D, Paddock S (2002) Reassessing the marijuana gateway effect. Addiction 97 (12): 1493–1504

    Google Scholar 

  131. Thanki D, Matias J, Griffiths P, Noor A, Olszewski D, Simon R, Vicente J (2012) Prevalence of daily cannabis use in the European Union and Norway. European Monitoring Center for Drugs and Drug Addiction Thematic Papers, Luxembourg,

    Google Scholar 

  132. UNODC (2017) United Nations Office on Drugs and Crime: Market analysis of plant-based drugs: Opiates, cocaine, cannabis. United Nations publication, Vienna

    Google Scholar 

  133. Wagner F, Anthony J (2002) Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. Am J Epidemiology 155 (10): 918–925

    Google Scholar 

  134. Werse B, Kamphausen G, Egger D, Sarvari L, Müller D (2015) MoSyD Jahresbericht 2014. Drogentrends in Frankfurt am Main. Centre for Drug Research, Frankfurt a. M.

    Google Scholar 

  135. Arzneimitteltelegramm (2017). Nabilon (Canemes) 48: 42–43

    Google Scholar 

  136. BFARM Bundesinstitut für Arzneimittel und Medizinprodukte. Zulassungsverfahren. http://www.bfarm.de/DE/Arzneimittel/zul/zulassungsverfahren/_node.html

  137. Grotenhermen F, Häßermann K (2007) Cannabis. Verordnungshilfe für für Ärzte. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  138. Kassenärztliche Vereinigung Westfalen-Lippe (KV) (2017) Cannabis als Kassenleistung. Information über die praktische Umsetzung. https://www.kvwl.de/arzt/verordnung/arzneimittel/info/invo/cannabis.pdf

  139. Lander N, Ben-Zvi Z, Mechoulam R, Martin B, Nordqvist M, Agurell S (1976) Total synthesis of cannabidiol and delta1-tetrahydrocannabinol metabolites. J Chem Soc Perkin 1: 8–16

    Google Scholar 

  140. Mechoulam R, Gaoni Y (1965) A total synthesis of DL-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 20: 3273–3275

    Google Scholar 

  141. MFG (2017) Ministerium für Gesundheit: Gesetz „Cannabis als Medizin in Kraft getreten” 10.03.2017. https://www.bundesgesundheitsministerium.de/ministerium/meldungen/2017/maerz/cannabis-als-medizin-inkrafttreten.html

  142. Müller-Wahl K, Grotenhermen F (2017) Medizinisches Cannabis: Die wichtigsten Änderungen. Dtsch Ärztebl 114: A352–356

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Entwicklungspsychologie und Biologische Psychologie, Psychologisches Institut der Universität Heidelberg, Universität Heidelberg, Heidelberg, Deutschland

    Miriam Schneider

  2. Forschungsgruppe Cannabinoide, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München, Deutschland

    Eva Hoch

  3. IFT Institut für Therapieforschung, München, Deutschland

    Roland Simon, Tim Pfeiffer-Gerschel & Ludwig Kraus

  4. Klinik für Innere Medizin 1 (Gastroenterologie, Hepatologie, Onkologie, Stoffwechsel- und Infektionskrankheiten, Psychosomatik), Klinikum Saarbrücken gGmbH, Saarbrücken, Deutschland

    Winfried Häuser

  5. Institut für Physiologische Chemie und Deutsches Resilienz Zentrum, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland

    Beat Lutz

Authors
  1. Miriam Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Hoch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roland Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tim Pfeiffer-Gerschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ludwig Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Winfried Häuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Beat Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, Ludwig-Maximilians-Universität München, München, Deutschland

    Eva Hoch  & Chris Maria Friemel  & 

  2. Entwicklungspsychologie und Biologische Psychologie, Psychologisches Institut der Universität Heidelberg, Universität Heidelberg, Heidelberg, Deutschland

    Miriam Schneider

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Schneider, M. et al. (2019). Cannabis, Cannabinoide und das Endocannabinoidsystem. In: Hoch, E., Friemel, C.M., Schneider, M. (eds) Cannabis: Potenzial und Risiko. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57291-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57291-7_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57290-0

  • Online ISBN: 978-3-662-57291-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation